The combined hormonal oral contraceptive pill (COC) has been available in the UK for the last 50 years. During this time, the dose of ethinyl estradiol has fallen from 100 mcg to 20-30 mcg, increasing patient acceptability and improving drug safety by reducing the risk of venous thromboembolism (VTE). At the same time, a number of non-contraceptive health benefits have emerged in association with combined hormonal contraception (CHC).
